| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 131.098 | 178.799 | 200.571 | 181.290 | 174.630 | 199.762 | 238.328 | 310.189 | 329.795 | 391.139 |
| Total Income - EUR | 131.110 | 183.116 | 202.100 | 183.716 | 178.221 | 200.699 | 239.809 | 315.170 | 334.914 | 410.671 |
| Total Expenses - EUR | 131.068 | 174.140 | 195.852 | 185.857 | 191.870 | 201.995 | 236.831 | 297.171 | 312.110 | 375.022 |
| Gross Profit/Loss - EUR | 43 | 8.976 | 6.248 | -2.141 | -13.649 | -1.296 | 2.977 | 17.999 | 22.804 | 35.649 |
| Net Profit/Loss - EUR | 36 | 7.831 | 2.509 | -3.977 | -15.431 | -3.254 | 579 | 14.910 | 19.957 | 23.945 |
| Employees | 4 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 4 | 5 |
Check the financial reports for the company - Dorisimo Pharma S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 5.513 | 2.382 | 1.170 | 1.137 | 32.105 | 22.810 | 13.810 | 5.333 | 1.070 | 87.549 |
| Current Assets | 39.400 | 67.208 | 85.297 | 71.233 | 80.874 | 81.620 | 94.608 | 118.444 | 123.296 | 165.477 |
| Inventories | 27.744 | 45.912 | 66.262 | 50.146 | 53.018 | 73.421 | 77.265 | 86.432 | 109.213 | 137.606 |
| Receivables | 11.063 | 4.184 | 18.153 | 19.205 | 25.616 | 5.920 | 15.604 | 29.962 | 11.518 | 8.939 |
| Cash | 593 | 17.113 | 881 | 1.883 | 2.239 | 2.279 | 1.740 | 2.049 | 2.565 | 18.931 |
| Shareholders Funds | 5.587 | 13.325 | 15.609 | 11.345 | -4.305 | -7.859 | -7.105 | 7.202 | 27.138 | 50.931 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 39.327 | 56.264 | 70.858 | 61.025 | 117.284 | 112.289 | 115.524 | 116.574 | 97.228 | 202.095 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "4773 - 4773" | |||||||||
| CAEN Financial Year |
4773
|
|||||||||
Comments - Dorisimo Pharma S.r.l.